In the British Journal of Cancer this week, a group of European researchers presents findings from phase I and open-label phase II studies of sorafenib and dacarbazine as a treatment for advanced melanoma. In the phase I study, the team analyzed maximum doses for acceptable toxicity. Then in the phase II study, 83 participants received the combination therapy, and the overall response rate was 12 percent, and stable disease was seen in 37 percent, the authors write.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Columbia University-led team used emergency contact information from medical records to create family trees and estimate disease heritability.

Parabon NanoLabs is partnering with law enforcement to use genetic genealogy approaches to solve cold cases, Buzzfeed News reports.

In Science this week: ancient Southeast Asian genomes provide insight on human migration, and more.

NPR says a new report recommends that former research chimpanzees should be moved to retirement sanctuaries unless that move would shorten their lives.